Aktie 002793 LUOXIN PHARMACEUTICALS GROUP STOCK CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Luoxin Pharmaceuticals Group Stock Co., Ltd.

Aktien

002793

CNE1000026S7

002793

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 14.05.2024 		% 5 Tage % 1. Jan.
4,88 CNY +2,95 % Intraday Chart für Luoxin Pharmaceuticals Group Stock Co., Ltd. +1,46 % -8,96 %
26.04. Luoxin Pharmaceuticals Group Stock Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
08.03. Luoxin Pharma erhält Recht zur Nutzung der fäkalen Mikrobiota-Transplantationstechnologie von Shenzhen Shishijijun Biotechnology MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Luoxin Pharma Gets Right to Use Shenzhen Shishijijun Biotechnology's Fecal Microbiota Transplant Technology
Tranche Update on Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback Plan announced on February 2, 2024.
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s Equity Buyback announced on February 2, 2024, has closed with 26,027,861 shares, representing 2.39% for CNY 99.99 million.
Luoxin Pharmaceuticals Group Stock Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.
Luoxin Pharmaceuticals Group Stock Co., Ltd. authorizes a Buyback Plan.
Luoxin Pharmaceuticals Posts Positive Results of Plucanatide Tablets' Trial
Two Luoxin Pharma Drugs Selected in China’s National Drug Procurement Program
Luoxin Health Technology Development Co., Ltd. announced that it has received CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd.'s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. agreed to acquire additional unknown stake in Luoxin Health Technology Development Co., Ltd. from Chengdu Deyi Xinhua Equity Investment Partnership Enterprise (LP) and Deyi Investment Management Co., Ltd. for CNY 1.
Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 5.7 million in funding from Luoxin Pharmaceuticals Group Stock Co., Ltd.
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Luoxin Pharmaceuticals Group Stock Co., Ltd. Elects Li Meng as Non-Independent Directors
Luoxin Pharmaceuticals' Injection Passes Regulatory Consistency Evaluation
Luoxin Pharmaceuticals Gets Regulatory Nod for Anti-Baterial Infection Drug
Luoxin Pharmaceuticals Group Stock Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 002793 Aktie
  4. Nachrichten Luoxin Pharmaceuticals Group Stock Co., Ltd.
  5. Andere Sprachen